It's interesting that "The M3 muscarinic receptor regulates fear and learning.." and "M3-muscarinic receptor knockout mice show a deficit in fear conditioning learning and memory".
"We demonstrate here that M3-muscarinic receptor knockout mice show a deficit in fear conditioning learning and memory."
It's interesting the Mucinex antagonizes the M3 receptor. Behavioral effects of Mucinex are very understudied.
M3 receptors also classically handle lung "learning" and response to allergens. https://pubmed.ncbi.nlm.nih.gov/8441331/ - "Muscarinic receptor subtypes in airways"
It's interesting that it's priced at $1850/month wholesale.
If TFA is to be believed, schizophrenia is quite common so the market is vast and the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply.
A mere 1M worldwide prescriptions (there's 6x that amount of people with schizophrenia in America alone) means 22 billions per year raw revenue.
They are not all going to get it right away, there are competitive drugs, it will first be used for patients who can’t tolerate current drugs. (Actually quite a few of them)
A lot of people with schizophrenia and related conditions are untreated. I know someone right now who is in her 40s and about to lose her housing who almost certainly has schizophrenia (sure has the thought disorder, if we want to pick her up to do something we might have to attempt it several times to pick her up, has grandiose delusions, no sign of hallucinations though, hasn’t really worked in 10 years) although she is undiagnosed and doesn’t believe there is anything wrong about her.
If you look at the homeless population I think you see a lot of schizophrenia and PSTD.
If they get 1M patients, they make $22B, so "the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply."?
It’s interesting to me that this is a combination medicine because the atypical antipsychotics (say https://en.wikipedia.org/wiki/Quetiapine) are “polypharmacy in a single molecule” in that they bind to both dopamine and serotonin receptors which cancel out terrible side effects such as tardive dyskinesia caused by earlier antipsychotics that work on the dopamine receptors (though most of those bind to histamine receptors causing strong sedation as well.)
It’s a combination medicine because the major effect, while deemed desirable in the brain, is not so in the body. The partner drug is a non-brain penetrating suppressant.
It would be a lot cheaper to do as the slavic shamans do: collect amanita muscaria caps, dry them by your campfire to denature the poisons, and … well, you can figure out the rest.
It's interesting that "The M3 muscarinic receptor regulates fear and learning.." and "M3-muscarinic receptor knockout mice show a deficit in fear conditioning learning and memory".
https://www.pnas.org/doi/10.1073/pnas.0914801107
"We demonstrate here that M3-muscarinic receptor knockout mice show a deficit in fear conditioning learning and memory."
It's interesting the Mucinex antagonizes the M3 receptor. Behavioral effects of Mucinex are very understudied.
M3 receptors also classically handle lung "learning" and response to allergens. https://pubmed.ncbi.nlm.nih.gov/8441331/ - "Muscarinic receptor subtypes in airways"
It's interesting that it's priced at $1850/month wholesale.
If TFA is to be believed, schizophrenia is quite common so the market is vast and the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply.
A mere 1M worldwide prescriptions (there's 6x that amount of people with schizophrenia in America alone) means 22 billions per year raw revenue.
They are not all going to get it right away, there are competitive drugs, it will first be used for patients who can’t tolerate current drugs. (Actually quite a few of them)
A lot of people with schizophrenia and related conditions are untreated. I know someone right now who is in her 40s and about to lose her housing who almost certainly has schizophrenia (sure has the thought disorder, if we want to pick her up to do something we might have to attempt it several times to pick her up, has grandiose delusions, no sign of hallucinations though, hasn’t really worked in 10 years) although she is undiagnosed and doesn’t believe there is anything wrong about her.
If you look at the homeless population I think you see a lot of schizophrenia and PSTD.
> and doesn’t believe there is anything wrong about her.
that is anosognosia: https://en.wikipedia.org/wiki/Anosognosia
How does this treatment compare to amisulpride or CBD for schizophrenia? https://www.google.com/search?q=amisulpride+cbd https://scholar.google.com/scholar?hl=en&q=amisulpride%20cbd...
I don't see how your comment follows.
If they get 1M patients, they make $22B, so "the usual excuses of "price has to be high to recoup R&D because of low demand" doesn't seem like it would apply."?
It seems like it does apply?
See https://en.wikipedia.org/wiki/Xanomeline/trospium_chloride
It’s interesting to me that this is a combination medicine because the atypical antipsychotics (say https://en.wikipedia.org/wiki/Quetiapine) are “polypharmacy in a single molecule” in that they bind to both dopamine and serotonin receptors which cancel out terrible side effects such as tardive dyskinesia caused by earlier antipsychotics that work on the dopamine receptors (though most of those bind to histamine receptors causing strong sedation as well.)
It’s a combination medicine because the major effect, while deemed desirable in the brain, is not so in the body. The partner drug is a non-brain penetrating suppressant.
It's effectively a partial agonist with different subreceptor affinities.
It would be a lot cheaper to do as the slavic shamans do: collect amanita muscaria caps, dry them by your campfire to denature the poisons, and … well, you can figure out the rest.